Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)